Shots:

• Orionis to receive research funding- convertible notes- clinical milestones along with royalties while Novartis gets access to Orionis’ Allo-Glue technology platform for designing novel therapies like protein degraders across multiple therapeutic areas
• The collaboration will combine Novartis’ expertise in drug discovery and development with Orionis’ innovative technologies for identifying and prioritizing new targets at a genome-wide scale
• Allo-Glue molecules are the class of allosterically acting small molecules- which act by altering the function of intracellular proteins engaging in molecular interactions and modulating disease target proteins

Click here to­ read full press release/ article 

 Ref: Businesswire  | Image: Novartis